Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18570515 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | Non-Final OA | LG CHEM, LTD. |
| 18706869 | COMPOSITIONS AND METHODS FOR TREATING CANCER VIA PTP1B INHIBITION | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18741322 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | The Regents of the University of California |
| 18897912 | ORGANIC COMPOUND, ORGANIC SEMICONDUCTOR DEVICE, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE | Non-Final OA | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. |
| 18893201 | FORMULATIONS OF ANTIVIRAL COMPOUNDS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18548784 | (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-ENECARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE | Non-Final OA | Northwestern University |
| 18015856 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | Non-Final OA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy